April 30, 2012 (Shareholders Foundation) -- An investigation on behalf of investors in Gen-Probe Incorporated (NASDAQ:GPRO) shares concerning whether the offer by Hologic, Inc to acquire Gen-Probe Incorporated at $82.75 per share and the buyout process are unfair to investors in NASDAQ:GPRO was announced.

The investigation by a law firm concerns whether certain officers and directors of Gen-Probe Incorporated breached their fiduciary duties owed to NASDAQ:GPRO investors in connection with the proposed acquisition.

On April 30, 2012, Hologic, Inc. (NASDAQ: HOLX) and Gen-Probe Incorporated (NASDAQ: GPRO) announced that their Boards of Directors have approved an agreement under which Hologic will acquire all of the outstanding shares of Gen-Probe for $82.75 per share in cash, or a total enterprise value of approximately $3.7 billion.

Therefore the investigation for Gen-Probe Incorporated (NASDAQ:GPRO) investors concerns whether the proposed transaction is unfair to Gen-Probe Incorporated (NASDAQ:GPRO)stockholders.

Following the takeover news, NASDAQ:GPRO shares jumped from $68.74 per share on Friday to $81.83 per share on Monday.

However, NASDAQ:GPRO shares traded as high as $86.66 per share on May 18, 2011 and Gen-Probes financial performance increased in recent years. Gen-Probes annual Revenue rose from $472.69 in 2008 to $576.23million in 2011.

Specifically, the investigation focuses on whether the Gen-Probe Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.